405 related articles for article (PubMed ID: 36227407)
21. Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma.
Li P; Dong N; Zeng Y; Liu J; Tang X; Wang J; Zhang W; Ye S; Zhou L; Chang AH; Liang A
Front Med; 2020 Dec; 14(6):811-815. PubMed ID: 32651937
[TBL] [Abstract][Full Text] [Related]
22. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.
Fenske TS; Zhang MJ; Carreras J; Ayala E; Burns LJ; Cashen A; Costa LJ; Freytes CO; Gale RP; Hamadani M; Holmberg LA; Inwards DJ; Lazarus HM; Maziarz RT; Munker R; Perales MA; Rizzieri DA; Schouten HC; Smith SM; Waller EK; Wirk BM; Laport GG; Maloney DG; Montoto S; Hari PN
J Clin Oncol; 2014 Feb; 32(4):273-81. PubMed ID: 24344210
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma.
Fried S; Shouval R; Walji M; Flynn JR; Yerushalmi R; Shem-Tov N; Danylesko I; Tomas AA; Fein JA; Devlin SM; Sauter CS; Shah GL; Kedmi M; Jacoby E; Shargian L; Raanani P; Yeshurun M; Perales MA; Nagler A; Avigdor A; Shimoni A
Transplant Cell Ther; 2023 Feb; 29(2):99-107. PubMed ID: 36343892
[TBL] [Abstract][Full Text] [Related]
24. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
Salles G; Chen JMH; Zhang I; Kerbauy F; Wu JJ; Wade SW; Nunes A; Feng C; Kloos I; Peng W; Snider JT; Maciel D; Chan K; Keeping S; Shah B
Adv Ther; 2024 May; 41(5):1938-1952. PubMed ID: 38494543
[TBL] [Abstract][Full Text] [Related]
25. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma.
Jiang VC; Hao D; Jain P; Li Y; Cai Q; Yao Y; Nie L; Liu Y; Jin J; Wang W; Lee HH; Che Y; Dai E; Han G; Wang R; Rai K; Futreal A; Flowers C; Wang L; Wang M
Mol Cancer; 2022 Sep; 21(1):185. PubMed ID: 36163179
[TBL] [Abstract][Full Text] [Related]
26. Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
Epperla N; Fenske TS; Lazarus HM; Hamadani M
Bone Marrow Transplant; 2015 Nov; 50(11):1393-404. PubMed ID: 26281033
[TBL] [Abstract][Full Text] [Related]
27. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
[TBL] [Abstract][Full Text] [Related]
28. Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective.
Goldsmith SR; Ghobadi A; Dipersio JF; Hill B; Shadman M; Jain T
Transplant Cell Ther; 2022 Nov; 28(11):727-736. PubMed ID: 35878743
[TBL] [Abstract][Full Text] [Related]
29. CAR T-Cell therapy for the management of mantle cell lymphoma.
Huang Z; Chavda VP; Bezbaruah R; Dhamne H; Yang DH; Zhao HB
Mol Cancer; 2023 Mar; 22(1):67. PubMed ID: 37004047
[TBL] [Abstract][Full Text] [Related]
30. Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma.
Anderson MK; Torosyan A; Halford Z
Ann Pharmacother; 2022 May; 56(5):609-619. PubMed ID: 34340597
[TBL] [Abstract][Full Text] [Related]
31. Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma.
Mian A; Hill BT
Expert Opin Biol Ther; 2021 Apr; 21(4):435-441. PubMed ID: 33566715
[No Abstract] [Full Text] [Related]
32. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
Wang M; Munoz J; Goy A; Locke FL; Jacobson CA; Hill BT; Timmerman JM; Holmes H; Jaglowski S; Flinn IW; McSweeney PA; Miklos DB; Pagel JM; Kersten MJ; Bouabdallah K; Khanal R; Topp MS; Houot R; Beitinjaneh A; Peng W; Fang X; Shen RR; Siddiqi R; Kloos I; Reagan PM
J Clin Oncol; 2023 Jan; 41(3):555-567. PubMed ID: 35658525
[TBL] [Abstract][Full Text] [Related]
33. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma.
Dhakal B; Shah N; Kansagra A; Kumar A; Lonial S; Garfall A; Cowan A; Poudyal BS; Costello C; Gay F; Cook G; Quach H; Einsele H; Schriber J; Hou J; Costa L; Aljurf M; Chaudhry M; Beksac M; Prince M; Mohty M; Janakiram M; Callander N; Biran N; Malhotra P; Otero PR; Moreau P; Abonour R; Iftikhar R; Silberman R; Mailankody S; Gregory T; Lin Y; Carpenter P; Hamadani M; Usmani S; Kumar S
Transplant Cell Ther; 2022 Jun; 28(6):284-293. PubMed ID: 35306217
[TBL] [Abstract][Full Text] [Related]
34. Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions.
Bond DA; Martin P; Maddocks KJ
J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33799484
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic options for relapsed/refractory mantle cell lymphoma.
Eyre TA; Cheah CY; Wang ML
Blood; 2022 Feb; 139(5):666-677. PubMed ID: 34679161
[TBL] [Abstract][Full Text] [Related]
36. Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma.
Dreger P; Laport GG
Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):100-7. PubMed ID: 18162229
[TBL] [Abstract][Full Text] [Related]
37. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2017 Aug; 92(8):806-813. PubMed ID: 28699667
[TBL] [Abstract][Full Text] [Related]
38. CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma.
Mohty R; Kharfan-Dabaja MA
Ther Adv Hematol; 2022; 13():20406207221142133. PubMed ID: 36544864
[TBL] [Abstract][Full Text] [Related]
39. Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma.
Yamasaki S; Chihara D; Kim SW; Izutsu K; Iwato K; Fukuda T; Uchida N; Amano I; Nakazawa H; Kuroda J; Hashimoto H; Ichinohe T; Kanda Y; Atsuta Y; Suzumiya J; Suzuki R
Ann Hematol; 2018 Aug; 97(8):1445-1452. PubMed ID: 29610968
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi.
Arcari A; Morello L; Vallisa D; Marcheselli L; Tecchio C; Quaglia FM; Tisi MC; Zilioli VR; Di Rocco A; Perrone T; Gini G; Dogliotti I; Bianchetti N; Bozzoli V; De Philippis C; Alvarez De Celis MI; Chiappella A; Fabbri A; Pelosini M; Merli M; Molinari AL; Sciarra R; Volpetti S; Hohaus S; Nassi L; Visco C
Leuk Lymphoma; 2021 Dec; 62(14):3474-3483. PubMed ID: 34625013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
